Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07609160 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals

StatusNot Yet Recruiting
PhaseNot applicable
Started2026-11-01
View on ClinicalTrials.gov ↗

Amendment history

2026-06-03
Study Identification, Study Status, Outcome Measures v1
Secondary endpoints16 to 18 entries
Muscle thickness Muscle echo intensity
Study titlerevised
Effectiveness of Combined GLP-1/GIP ReceptorDual Agonist Therapy and Structured Exercise on Skeletal Muscle [...]
2026-05-21
Original filing
Acibadem University
70 trials monitored
See 2 trials at risk
Diabetes
4,247 trials monitored
See 176 trials at risk
Obesity
3,523 trials monitored
See 133 trials at risk
Type 2 Diabetes
2,082 trials monitored
See 101 trials at risk
This randomized controlled trial aims to investigate the effects of a 24-week home-based progressive resistance exercise program combined with tirzepatide treatment on skeletal muscle mass, muscle quality, and functional capacity in overweight and obese individuals. A total of 108 participants initiating tirzepatide therapy will be randomized to either exercise plus pharmacotherapy or pharmacotherapy alone. The primary outcome is change in thigh muscle thickness and echo intensity assessed by ultrasonography.
Trial Details
NCT Number NCT07609160
Lead Sponsor Acibadem University
Conditions Obesity, Sarcopenia, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Enrollment 108 participants
Start Date 2026-11-01
Primary Completion 2027-11-30 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-04